New · CUSIP 14070B309 · who reports it, how much, and how much it matters to them
20 of the 720 hedge fund managers we track reported shares of Capricor Therapeutics, Inc. (Nasdaq: CAPR) on Form 13F for 30 June 2026. Between them they reported USD 261m. The largest position belongs to Suvretta Capital Management, at USD 99m. The manager with the most riding on it is DG Capital Management, where it is 3.1% of the reported book.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Suvretta Capital Management4 funds on PPLI.com | USD 99m | 1.8% |
| 2 | Ra Capital Management1 fund on PPLI.com | USD 36m | 0.3% |
| 3 | Boxer Capital Management1 fund on PPLI.com | USD 34m | 2.5% |
| 4 | Citadel Advisors32 funds on PPLI.com | USD 20m | 0.0% |
| 5 | DG Capital Management3 funds on PPLI.com | USD 15m | 3.1% |
| 6 | Balyasny Asset Management25 funds on PPLI.com | USD 12m | 0.0% |
| 7 | J. Goldman & Co.1 fund on PPLI.com | USD 10m | 0.3% |
| 8 | RTW Investments2 funds on PPLI.com | USD 6m | 0.1% |
| 9 | Millennium Management6 funds on PPLI.com | USD 5.6m | 0.0% |
| 10 | Palo Alto Investors6 funds on PPLI.com | USD 5.5m | 0.8% |
| 11 | Boothbay Fund Management2 funds on PPLI.com | USD 4.6m | 0.1% |
| 12 | D. E. Shaw & Co.15 funds on PPLI.com | USD 3m | 0.0% |
| 13 | PFM Health Sciences3 funds on PPLI.com | USD 2.9m | 0.3% |
| 14 | Marshall Wace LLP84 funds on PPLI.com | USD 2.4m | 0.0% |
| 15 | POINT72 Asset Management17 funds on PPLI.com | USD 2.3m | 0.0% |
| 16 | Rock Springs Capital Management2 funds on PPLI.com | USD 1.8m | 0.1% |
| 17 | Aquatic Capital Management3 funds on PPLI.com | USD 632,000 | 0.0% |
| 18 | Anson Funds Management8 funds on PPLI.com | USD 602,000 | 0.0% |
| 19 | Squarepoint Ops7 funds on PPLI.com | USD 475,000 | 0.0% |
| 20 | Tudor Investment Corporation10 funds on PPLI.com | USD 381,000 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | DG Capital Management | USD 15m | 3.1% |
| 2 | Boxer Capital Management | USD 34m | 2.5% |
| 3 | Suvretta Capital Management | USD 99m | 1.8% |
| 4 | Palo Alto Investors | USD 5.5m | 0.8% |
| 5 | Ra Capital Management | USD 36m | 0.3% |
| 6 | J. Goldman & Co. | USD 10m | 0.3% |
| 7 | PFM Health Sciences | USD 2.9m | 0.3% |
| 8 | Rock Springs Capital Management | USD 1.8m | 0.1% |
| 9 | Boothbay Fund Management | USD 4.6m | 0.1% |
| 10 | RTW Investments | USD 6m | 0.1% |
Capricor Therapeutics, Inc. trades under the symbol CAPR on the Nasdaq. Its CUSIP, the code used on Form 13F, is 14070B309.
20 of the 720 hedge fund managers PPLI.com tracks reported Capricor Therapeutics, Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Suvretta Capital Management (USD 99m), Ra Capital Management (USD 36m), Boxer Capital Management (USD 34m), Citadel Advisors (USD 20m) and DG Capital Management (USD 15m).
20 managers in our coverage reported it, and between them they run 232 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
DG Capital Management, where the position was 3.1% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Capricor Therapeutics, Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.